JP Morgan Healthcare: where science, tech and finance collideWelcome to 2019! Hopefully by now you’re managing to ease yourself back into things, no doubt with good Share XJP Morgan Healthcare: where science, tech and finance collidehttps://pharmaphorum.com/views-analysis-sales-marketing/jp-morgan-healthcare-science-tech-finance-collide/
Why pharma’s focus on patients requires less patienceHave you missed me? I certainly wouldn’t be so egotistical to assume that anyone has, but bizarrely it’s Share XWhy pharma’s focus on patients requires less patiencehttps://pharmaphorum.com/patients/pharmas-focus-patients-requires-less-patience/
Can ‘design thinking’ revolutionise pharma’s culture?As part of pharmaphorum’s ‘eye-on-innovation’ series, Paul Tunnah speaks to UCB’s head of innovation, Gregory Miller, about how Share XCan ‘design thinking’ revolutionise pharma’s culture?https://pharmaphorum.com/views-and-analysis/can-design-thinking-revolutionise-pharmas-culture/
Merck KGaA celebrates 350 years of innovationAs part of pharmaphorum’s eye-on-innovation interview series, Paul Tunnah speaks to Merck Biopharma’s vice president of innovation Ulrich Share XMerck KGaA celebrates 350 years of innovationhttps://pharmaphorum.com/views-analysis-digital/merck-kgaa-celebrates-350-years-innovation/
Innovation, endpoints and education – what’s in store for pharma in future-healthcare?As part of pharmaphorum’s ‘eye-on-innovation’ interview series, Paul Tunnah speaks to Bayer’s Chief Marketing Officer Pharmaceuticals, Sebastian Guth, Share XInnovation, endpoints and education – what’s in store for pharma in future-healthcare?https://pharmaphorum.com/views-and-analysis/innovation-endpoints-education-whats-store-pharma-future-healthcare/
Tackling the rare disease conundrum with passion, innovation and investmentThe first Cambridge Rare Disease Summit brought all stakeholders together to discuss the key issues and, in doing Share XTackling the rare disease conundrum with passion, innovation and investmenthttps://pharmaphorum.com/views-and-analysis/tackling-the-rare-disease-conundrum-with-passion-innovation-and-investment/
Live Tweetchat: Managing COPD in the real worldWorking in partnership, Atlantis Healthcare and pharmaphorum present a Tweetchat focussed on the real world challenges patients face in Share XLive Tweetchat: Managing COPD in the real worldhttps://pharmaphorum.com/articles/live-tweetchat-managing-copd-in-the-real-world-2/
Available on-demand: COPD, connecting real world needs to patient centric solutions COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and Share XAvailable on-demand: COPD, connecting real world needs to patient centric solutionshttps://pharmaphorum.com/debates-insight-patients/live-webinar-debate-feb-4th-copd-connecting-real-world-needs-to-patient-centric-solutions-price-is-right-uk-niche-market-access-2/
Available on-demand: The Price is Right? – Delivering UK access for niche patient populations With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what Share XAvailable on-demand: The Price is Right? – Delivering UK access for niche patient populationshttps://pharmaphorum.com/debates-insight-market-access/live-webinar-the-price-is-right-uk-niche-market-access/
